KLKristen E. Limbach

Kristen E. Limbach

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kristen E. Limbach has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Novel Radiomics-Integrated Panel for Preoperative Stratification of Pancreatic Neuroendocrine Tumors (PNETs)

    by Abdallah Attia, Jihun Hamm, Mahmoud A. AbdAlnaeem, Zhengming Ding, Michael O’Rorke, Joseph Dillon, Mary Maluccio, Nicholas Skill, Kristen Limbach

    Background. Preoperative risk stratification of pancreatic neuroendocrine tumors (PNETs) is constrained by the unavailability of histologic grade before resection. We hypothesized that a panel of biologically informed CT-radiomic signatures, combined with patient-level Δ-radiomics referenced to the contralateral pancreas, would support preoperative discrimination of progression and grade in a two-center pilot cohort. Methods. Forty-four patients with histologically confirmed PNET who underwent contrast-enhanced preoperative CT and surgical resection at two academic centers were analyzed. Lesion and contralateral non-tumor-bearing pancreatic parenchyma regions of interest were revised in 3D Slicer by a board-certified pancreatic surgeon and verified intraoperatively against surgical pathology. PyRadiomics v3.0 features were extracted with IBSI-concordant settings. Parametric ComBat batch correction was applied across the two centers (biological-covariate balance verified beforehand), and Δ-radiomic features (lesion combat–pancreas combat) were computed for the 106 intensity/texture primitives. We constructed a panel of biology-informed hybrid signatures partitioned into a preoperative lesion-only family (Family A; seven signatures) and a preoperative Δ-radiomic family (Family B; three signatures). Candidate features were filtered through correlation clustering, baseline-adjusted likelihood-ratio testing with Benjamini–Hochberg FDR control, and 100-bootstrap stability selection. Three predictor blocks were compared per target with three classifiers each (Logistic Regression, Random Forest, Gradient Boosting): M0 (five-variable clinical baseline), MA (M0 + Family A), and MB (M0 + Family B). Discrimination was reported as AUC with bootstrap 95% CI; calibration was assessed using the Brier score and TRIPOD-recommended calibration intercept and slope; and cross-center generalization was evaluated with leave-one-center-out (LOCO) cross-validation. Univariable Cox regression with bootstrap and permutation inference was used for progression-free survival (PFS). Results. The cohort had 16 progression events and eight deaths (median follow-up was 38 months, IQR 14–59). Prespecified clinical–radiomic and Δ-radiomic signatures were associated with progression-free survival, including B2 = ΔBusyness × Ki-67 (HR 0.38, 95% CI 0.19–0.76, p = 0.006). For progression prediction, the Δ-radiomic model achieved the strongest discrimination, with a nested cross-validation AUC of 0.85 and leave-one-center-out AUC of 0.87. For higher-grade disease, radiomic models also demonstrated high discrimination, with AUCs up to 0.93. Conclusions. Radiomics-derived shape and texture features, especially when combined with clinical markers, may noninvasively identify aggressive PNET phenotypes and support preoperative risk stratification. Prospective validation in larger multicenter cohorts is warranted.


  • Open Access

    Complications of ovarian metastases from well-differentiated small bowel neuroendocrine neoplasms: a focus on bowel and ureteral obstruction

    by Sydney J. Wellens, Nicholas J. Skill, Kevin M. Sullivan, Mary A. Maluccio, Kristen E. Limbach

  • Open Access

    Survival Benefits of GLP-1 Receptor Agonists in Patients with Neuroendocrine Neoplasms: A Large-Scale Propensity-Matched Cohort Study

    by Manal S. Fawzy, Awwad Alenezy, Jessan A. Jishu, Issa Khan, Ahmad Dessouky, Ahmed Abdelmaksoud, Kristen E. Limbach, Eman A. Toraih

    Background: Neuroendocrine neoplasms (NENs) represent a heterogeneous group of malignancies that consist of two major subtypes: neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs). Glucagon-like peptide-1 receptor agonists (GLP-1Ra) have demonstrated favorable results in preclinical studies, but their impact on NEN outcomes remains unexplored. Methods: Using the TriNetX US Research Network, we identified adult patients with NEN and either diabetes or obesity. After 1:1 propensity score matching based on demographics, comorbidities, procedures, and medication use, we compared survival outcomes between patients who received GLP-1Ra after NEN diagnosis and those who did not. Results: Among 32,464 eligible patients, 3139 received GLP-1Ra and 29,325 did not. After propensity matching, each cohort included 3043 patients with well-balanced baseline characteristics. During follow-up periods extending up to 15 years, all-cause mortality occurred in 356 (11.7%) GLP-1Ra users versus 753 (24.7%) non-users, representing a 13.0% absolute risk reduction (p < 0.001). GLP-1Ra use was associated with significantly improved survival (HR = 0.56, 95%CI = 0.49–0.63, p < 0.001). Both well-differentiated (HR = 0.52) and poorly differentiated tumors (HR = 0.56) showed significant improvement. Among primary sites, lung NENs demonstrated the most pronounced benefit (HR = 0.42). Tirzepatide showed the strongest association with reduced mortality (HR = 0.16), followed by semaglutide (HR = 0.27) and dulaglutide (HR = 0.52). Results: In this large propensity-matched study, GLP-1Ra use was associated with a 44.3% reduction in mortality risk among NEN patients with diabetes or obesity. The magnitude of the observed benefit suggests a potential role for GLP-1Ra as adjunctive therapy in this patient population. Prospective clinical trials are warranted to confirm these findings and explore underlying mechanisms.


  • Open Access

    Liver Resection for Gastroenteropancreatic Neuroendocrine Tumors with Extrahepatic Disease

    by Kelly M. Mahuron, Kristen E. Limbach, Matthew C. Hernandez, Philip H. G. Ituarte, Daneng Li, Jonathan Kessler, Gagandeep Singh

    Background: Although survival outcomes for neuroendocrine liver metastases (NETLM) are improved with liver-direct therapies (LDT), including hepatic debulking and nonsurgical trans-arterial embolization, the benefit is less established in the setting of concurrent extrahepatic disease (EHD). We performed a population-based study to characterize the rates of LDT being performed for NETLM with EHD patients and whether LDT is associated with survival outcomes. Methods: Patients with NETLM and EHD were identified using the California Cancer Registry database merged with data from the California Office of Statewide Health Planning and Development between 2000 and 2012. Demographics, clinical characteristics, and survival outcomes were analyzed for these patients with and without LDT. Results: 327 NETLM patients with EHD were identified. EHD sites included lung, peritoneum, bone, and brain. A total of 71 (22%) of these patients underwent LDT. Compared to NETLM with EHD patients who did not undergo LDT, patients who received LDT had longer median overall survival (27 vs. 16 months, p = 0.006). Within the LDT group, 23 patients underwent liver resection. Liver resection was associated with longer median overall survival compared to nonsurgical LDT (138 vs. 13 months, p < 0.001). Conclusions: LDT candidacy should be determined for patients on a case-by-case basis, but the presence of EHD should not preclude LDT with appropriate patient selection.


  • Open Access

    Liver-Directed Therapy in Neuroendocrine Neoplasms Metastatic to Both Liver and Bone

    by Kristen E. Limbach, Kelly M. Mahuron, Aaron T. Scott, Philip H. G. Ituarte, Gagandeep Singh

    Bone metastases from gastroenteropancreatic neuroendocrine neoplasms (GEPNENs) have been associated with poor prognosis, but it is unclear whether patients with concurrent bone metastases who receive liver-directed therapy (LDT) would derive survival benefit. The California Cancer Registry dataset, merged with data from the California Office of Statewide Health Planning and Development, was used to perform a retrospective study of GEPNENs metastatic to both liver and bone between 2000 and 2012. A total of 203 patients were identified. Of these, 14.8% underwent LDT after bone metastasis diagnosis, 22.1% received LDT prior to that diagnosis, and 63.1% never received LDT. The median overall survival from the time of bone metastasis diagnosis was significantly longer in those that received LDT after diagnosis when compared with those that never received LDT (p = 0.005) and was not significantly different from the median overall survival of those that had received LDT prior to diagnosis (p = 0.256). LDT may still be associated with improved survival even after a diagnosis of bone metastasis.